483 Results (Page 1 of 20)
France Markets Research Reports
France Bariatric Surgery Devices Market Analysis
The France Bariatric Surgery Devices Marketwas valued at $73.2 Mn in 2023 and is projected to grow at a CAGR of 4.2% from 2023 to 2023, to $97.6 Mn by 2030. The market for bariatric surgical devices is being driven primarily by increased adult obesity rates, which are a result of changing lifestyles and consuming excessive amounts of calories. Over the course of the projection period, it is also expected that the demand for bariatric operations will increase as a result of growing public awareness of the harmful food and beverage options available in the market and how they affect body mass index (BMI), which will fuel the expansion of the bariatric surgery devices market. The prominent players in the market are Apollo Endosurgery, TransEnterix, Stryker, Medtronic, B. Braun, Peters Surgical, Johnson & Johnson, Cousin Surgery among others.
France Growth Hormone Deficiency Clinical Trials Market Analysis
This report presents a strategic analysis of the France Growth Hormone Deficiency Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the France Growth Hormone Deficiency Clinical Trials Market, offering unmatched value, accuracy and expert insights.
France Genomic Diagnostics Market Analysis
France Genomic Diagnostics Market was valued at $897.88 Mn in 2023 and is predicted to grow at a CAGR of 15.5% from 2023 to 2030, to $2,462.01 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, personalized medicine and companion diagnostics, and technological advancements. The industry is primarily dominated by Illumina, 23andMe, Myriad Genetics, and Amgen among others.
France Hemodialysis Vascular Grafts Market Analysis
France Hemodialysis Vascular Grafts Market was valued at $5.76 Bn in 2023 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030, to $7.63 Bn by 2030. The key drivers of this industry include the rising prevalence of diabetes and hypertension, the aging population, and technological advancements. The industry is primarily dominated by W. L. Gore, C. R. Bard, Vascudyne, and LeMaitre among others.
France Contact Lenses Market Analysis
France Contact Lenses Market was valued at $471.35 Mn in 2023 and is predicted to grow at a CAGR of 7.9% from 2023 to 2030, to $802.59 Mn by 2030. The key drivers of this industry include high disposable income, an aging population, and technological advancements. The industry is primarily dominated by Bausch and Lomb, CooperVision, Alcon Vision, and Essilor among others.
France Obesity Drugs Market Analysis
This report presents a strategic analysis of the France Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the France Obesity Drugs Market, offering unmatched value, accuracy and expert insights.
France Healthcare Reimbursement Market Analysis
This report presents a strategic analysis of the France Healthcare Reimbursement Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the France Healthcare Reimbursement Market, offering unmatched value, accuracy and expert insights.
France Kyphoplasty Market Analysis
The French kyphoplasty market was valued at $3.2 Mn in 2023 and is predicted to grow at a CAGR of 5.53% from 2023 to 2030, to $4.6 Mn by 2030. The key drivers of the market include the increased prevalence of osteoporosis and spine fractures, continuous technological advancements, kyphoplasty as a superior alternative treatment, and improved patient compliance. The key players of the France kyphoplasty market are IZI Medical, MicroPort Scientific Corporation, Medtronic, Stryker, DePuy Synthes, and Smith & Nephew, among others.
France Dental Caries Detectors Market Analysis
The France Dental Caries Detectors Market was valued at $6.3 Mn in 2023 and is predicted to grow at a CAGR of 7.9% from 2023 to 2030, to $10.7 Mn by 2030. France Dental Caries Detectors Market is growing due to Increasing Dental Awareness and Education, Prevalence of dental caries, and Advanced imaging and diagnostics. The market is primarily dominated by players such as Carestream Denta, Planmeca Oy, Acteon Group, AdDent Inc., Air Techniques Inc., Dentlight Inc. Smile 360, Pacific Dental Services, Dental Services Group, Sirona Dental Systems, Dentsply Sirona.
France Clinical Nutrition for Diabetes Care Market Analysis
The France Clinical Nutrition for Diabetes Care Market was valued at $59.13 Mn in 2023 and is predicted to grow at a CAGR of 3.78% from 2023 to 2030, to $76.66 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Nutribio, Sanofi S.A., and Baxter International Inc. among others.
France Pharmacy Automation Device Market Analysis
The France Pharmacy Automation Device Market was valued at $151.2 Mn in 2023 and is predicted to grow at a CAGR of 8.9% from 2023 to 2030, to $274.7 Mn by 2030. France Pharmacy Automation Device Market is growing due to Growing Healthcare Expenses, Increased Medication Errors, Technological Advancements. The market is primarily dominated by players such as Amerisource Bergen Corporation, Accu-Chart Plus Healthcare Systems, Omnicell, Inc., McKesson Corporation; Pearson Medical Technologies, Baxter; Talyst, LLC.
France Cardiac Pacemakers Market Analysis
The France Cardiac Pacemakers Market was valued at $111.29 Mn in 2023 and is predicted to grow at a CAGR of 2.2% from 2023 to 2030, to $129.60 Mn by 2030. The key drivers of this industry include the aging population, technological advancements, and healthcare system. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
France Chronic Myelogenous Leukemia Therapeutics Market Analysis
France Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.
France Chronic Lymphocytic Leukemia Therapeutics Market Analysis
France Chronic Lymphocytic Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A typical form of adult Leukemia known as chronic lymphocytic Leukemia (CLL) is characterized by an excessive production of aberrant white blood cells. In most cases, it happens when the bone marrow generates damaged cells, which interfere with the formation of antibodies and eventually render them ineffective against infections. The rise in chronic lymphocytic Leukemia cases is anticipated to fuel market expansion throughout the anticipated time frame. The market will rise as a result of the various treatment options available and the familial history of chronic lymphocytic leukemia. The high cost of treatment, however, is anticipated to limit market expansion. AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Exelixis, Inc., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., MorphoSys AG, Ono Pharmaceutical Co., Ltd., and Amgen, Inc. are a few of the leading companies profiled in the chronic lymphocytic leukemia therapeutics market report.
France Morquio Syndrome (MPS-IV) Therapeutics Market Analysis
France Morquio Syndrome (MPS-IV) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Major global players in Morquio Syndrome (MPS-IV) Therapeutics Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Therapeutics, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.
France Lysosomal Storage Disease Therapeutics Market Analysis
France lysosomal storage disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in this market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, Sigilon Therapeutics, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
France Interstitial Cystitis Therapeutics Market Analysis
France Interstitial Cystitis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 30. The global market is expanding as a result of a rise in the frequency of interstitial cystitis and support for research. Major global players in this market are Amneal Pharmaceuticals Inc, Astellas Pharma Inc, Aurobindo Pharma Ltd, Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Co, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd, Mission Pharmacal Co, Perrigo Co. Plc, Pfizer Inc, Purdue Pharma LP, Seikagaku Corp, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc.
France Hypophosphatasia (HPP) Therapeutics Market Analysis
France hypophosphatasia (HPP) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for hypophosphatasia is anticipated to grow as a result of an increase in the ailment's prevalence, a family history of it, a robust product pipeline, and increased financing for research to create cutting-edge, new treatments for the condition. Major global players in the hypophosphatasia therapeutic market are Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group Plc., Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc, Ultragenyx Pharmaceutical Inc, BioMarin Pharmaceutical Inc, Prior Company Ltd, Enobia Pharma Corporation, AstraZeneca Plc, Rallybio Corporation.
France Hypertrophic Cardiomyopathy Therapeutics Market Analysis
France hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.
France Huntington's Disease Therapeutics Market Analysis
France huntington's disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease. Some of the key players in the global Huntington's Disease Therapeutics Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals,Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Therapeutics (Australia) and som biotech (spain).
France Hereditary Angioedema Therapeutics Market Analysis
France Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.
France Hepatorenal Syndrome Therapeutics Market Analysis
France Hepatorenal Syndrome Therapeutics (HRS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. People with cirrhosis or acute liver failure who develop kidney impairment are said to have hepatorenal syndrome (HRS), a serious consequence of advanced liver disease. Renal function improvement and halting further decline are the main objectives of treatment for hepatorenal syndrome. The market for HRS Therapeutics is being driven by an increase in the number of patients with liver illnesses, ongoing medical technology breakthroughs, government efforts, and partnerships and collaborations amongst pharmaceutical companies. Ferring Pharmaceuticals, Hospira, Pfizer, Sandoz, Novartis, Grifols, CSL Behring, Octa pharma, and Baxalta are major international participants in the market for treatments for hepatocellular syndrome.
France Clinical Nutrition for Cancer Care Market Analysis
The France Clinical Nutrition for Cancer Care Market was valued at $154.8 Mn in 2023 and is predicted to grow at a CAGR of 4.04% from 2023 to 2030, to $204.3 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the France Clinical Nutrition for Cancer Care Market are Danone Nutricia, Laboratories Lactalis Nutrition Santé (LNS), Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
France Gram-Negative Infection Therapeutics Market Analysis
The France Gram-Negative Infection Therapeutics Market was valued at $409.1 Mn in 2023 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030 to $571.8 Mn by 2030. This growth is fuelled by the rising prevalence of healthcare-associated infections (HAIs), affecting approximately 750,000 patients yearly, with a notable portion attributed to gram-negative bacteria. Key players in this market include Pfizer, Sanofi, Baxter, Takeda and others.
France Home Infusion Therapy Market
The France Home Infusion Therapy Market was valued at $988.9 Mn in 2023 and is predicted to grow at a CAGR of 7.1% from 2023 to 2030, to $1598.4 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the France Home Infusion Therapy Market are Option Care Health, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.